Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Open Source Software
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers.
Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-?- and TNF-a-co-producing T cell-mediated antitumor immunity.
Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy.
Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rß2 or IL-18Ra.
Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
Potent and long-term antiangiogenic efficacy mediated by FP3-expressing oncolytic adenovirus.
Quantitative impact of immunomodulation versus oncolysis with cytokine-expressing virus therapeutics.
Treatment strategies for combining immunostimulatory oncolytic virus therapeutics with dendritic cell injections.
Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model.
Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer.